Selegiline is a MAO-B inhibitor used in conjunction with L-DOPA in severe parkinsonism to prevent end of dose deterioration. Some evidence suggests that selegiline is unique amongst anti-parkinsonian drugs in preventing disease progression and some sources have suggested its use alone in early Parkinson's disease. However, recent studies have cast some doubt on the efficacy of selegiline and it may not after all confer any neuroprotective effect and may in fact increase mortality.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.